Medy-Tox Inc (086900) — Capital Reinvestment Ratio
Medy-Tox Inc (086900) has a Capital Reinvestment Ratio of 0.34x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩19.03 Billion) in capital expenditures (₩6.46 Billion). Check Medy-Tox Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Medy-Tox Inc Capital Reinvestment Ratio (2013–2024)
This chart tracks Medy-Tox Inc's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Medy-Tox Inc.
Annual Capital Reinvestment Ratio for Medy-Tox Inc (2013–2024)
Year-by-year Capital Reinvestment Ratio for Medy-Tox Inc from 2013 to 2024. See Medy-Tox Inc (086900) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.51x | ₩36.89 Billion | ₩18.72 Billion | ▼ -81.7% |
| 2023 | 2.77x | ₩13.52 Billion | ₩37.47 Billion | ▲ +633.7% |
| 2022 | 0.38x | ₩26.20 Billion | ₩9.90 Billion | ▼ -56.9% |
| 2021 | 0.88x | ₩19.97 Billion | ₩17.51 Billion | ▼ -40.5% |
| 2020 | 1.47x | ₩27.93 Billion | ₩41.14 Billion | ▲ +136.2% |
| 2019 | 0.62x | ₩33.70 Billion | ₩21.02 Billion | ▲ +304.2% |
| 2018 | 0.15x | ₩55.07 Billion | ₩8.50 Billion | ▼ -77.1% |
| 2017 | 0.67x | ₩56.55 Billion | ₩38.04 Billion | ▼ -74.8% |
| 2016 | 2.67x | ₩54.10 Billion | ₩144.67 Billion | ▲ +76.9% |
| 2015 | 1.51x | ₩22.37 Billion | ₩33.81 Billion | ▲ +857.5% |
| 2014 | 0.16x | ₩105.38 Billion | ₩16.64 Billion | ▼ -84.2% |
| 2013 | 1.00x | ₩16.60 Billion | ₩16.55 Billion | — |